MA54809A - Composition pharmaceutique comprenant du macitentan pour le traitement de l'hypertension pulmonaire thromboembolique chronique - Google Patents

Composition pharmaceutique comprenant du macitentan pour le traitement de l'hypertension pulmonaire thromboembolique chronique

Info

Publication number
MA54809A
MA54809A MA054809A MA54809A MA54809A MA 54809 A MA54809 A MA 54809A MA 054809 A MA054809 A MA 054809A MA 54809 A MA54809 A MA 54809A MA 54809 A MA54809 A MA 54809A
Authority
MA
Morocco
Prior art keywords
macitentan
treatment
pharmaceutical composition
pulmonary hypertension
thromboembolic pulmonary
Prior art date
Application number
MA054809A
Other languages
English (en)
Inventor
Dénes Csonka
Wassim Fares
Hans Hoogkamer
Koen Torfs
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69177170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54809(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA54809A publication Critical patent/MA54809A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054809A 2019-01-25 2020-01-24 Composition pharmaceutique comprenant du macitentan pour le traitement de l'hypertension pulmonaire thromboembolique chronique MA54809A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP2019051874 2019-01-25
EP2019060152 2019-04-18
EP2019066495 2019-06-21
EP2019067187 2019-06-27

Publications (1)

Publication Number Publication Date
MA54809A true MA54809A (fr) 2022-04-20

Family

ID=69177170

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054809A MA54809A (fr) 2019-01-25 2020-01-24 Composition pharmaceutique comprenant du macitentan pour le traitement de l'hypertension pulmonaire thromboembolique chronique

Country Status (18)

Country Link
US (2) US20220096474A1 (fr)
EP (1) EP3914253A1 (fr)
JP (1) JP2022522612A (fr)
KR (1) KR20210120024A (fr)
CN (1) CN113329751A (fr)
AU (1) AU2020211014A1 (fr)
BR (1) BR112021014499A2 (fr)
CA (1) CA3127271A1 (fr)
CL (1) CL2021001933A1 (fr)
CO (1) CO2021011046A2 (fr)
IL (1) IL284988A (fr)
JO (1) JOP20210198A1 (fr)
MA (1) MA54809A (fr)
MX (1) MX2021008574A (fr)
PH (1) PH12021551728A1 (fr)
SG (1) SG11202106312SA (fr)
TW (1) TW202042818A (fr)
WO (1) WO2020152308A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3897646B1 (fr) 2018-12-21 2024-05-22 Actelion Pharmaceuticals Ltd Macitentan pour le traitement de l'hypertension artérielle pulmonaire
TW202042818A (zh) * 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
US20240423980A1 (en) * 2023-06-23 2024-12-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods of preventing a venous thromboembolic event
CN120267675A (zh) * 2025-04-16 2025-07-08 江苏济茗医药有限公司 一种阿普昔腾坦和利尿剂的组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693372A1 (fr) 2000-12-18 2006-08-23 Actelion Pharmaceuticals Ltd. Nouveaux sulfamides et leur utilisation comme antagoniste du récepteur d'endotheline
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
MX350011B (es) 2008-08-13 2017-08-22 Actelion Pharmaceuticals Ltd Composiciones terapeuticas que contienen macitentan.
IL266518B2 (en) 2016-11-10 2026-05-01 Arena Pharm Inc Methods for treating pulmonary hypertension with combinations of relinfag and other substances
WO2018153925A1 (fr) * 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Compositions pharmaceutiques stables comprenant du macitentan
UA126122C2 (uk) 2017-02-27 2022-08-17 Ідорсія Фармасьютікалз Лтд Комбінації похідної 4-піримідинсульфаміду з активними інгредієнтами для лікування захворювань, пов'язаних з ендотеліном
EP3897646B1 (fr) 2018-12-21 2024-05-22 Actelion Pharmaceuticals Ltd Macitentan pour le traitement de l'hypertension artérielle pulmonaire
TW202042818A (zh) * 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
TW202103703A (zh) 2019-04-05 2021-02-01 瑞士商艾克泰聯製藥有限公司 用於治療門脈肺高血壓之方法
JOP20220126A1 (ar) 2019-11-26 2023-01-30 Actelion Pharmaceuticals Ltd تركيبة صيدلانية لعلاج أمراض الأوعية الدموية الرئوية و/أو خلل وظيفي في القلب لمرضى فونتان المُخفّف

Also Published As

Publication number Publication date
BR112021014499A2 (pt) 2021-09-28
US11612600B2 (en) 2023-03-28
CN113329751A (zh) 2021-08-31
SG11202106312SA (en) 2021-07-29
WO2020152308A1 (fr) 2020-07-30
JOP20210198A1 (ar) 2023-01-30
IL284988A (en) 2021-09-30
JP2022522612A (ja) 2022-04-20
CL2021001933A1 (es) 2022-04-08
KR20210120024A (ko) 2021-10-06
AU2020211014A1 (en) 2021-09-16
CO2021011046A2 (es) 2022-01-17
CA3127271A1 (fr) 2020-07-30
PH12021551728A1 (en) 2022-04-04
MX2021008574A (es) 2021-08-11
US20220096474A1 (en) 2022-03-31
TW202042818A (zh) 2020-12-01
US20220331319A1 (en) 2022-10-20
EP3914253A1 (fr) 2021-12-01

Similar Documents

Publication Publication Date Title
FR25C1005I2 (fr) Compositions comprenant des polypeptides actriia pour leur utilisation dans le traitement de l'hypertension pulmonaire
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
EP3755804A4 (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
EP3645044A4 (fr) Utilisation d'anticorps dirigés contre une famille à similarité de séquence 19, membre a5, pour le traitement du glaucome
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3634426A4 (fr) Compositions pour le traitement d'une fibrose
EP3445352A4 (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
MA55490A (fr) Mutéine de lipocaline pour le traitement de l'asthme
EP3877418A4 (fr) Schéma posologique d'anticorps anti-tigit pour le traitement du cancer
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3810091A4 (fr) Méthodes et compositions pour le traitement de l'hypertension pulmonaire
EP3911329A4 (fr) Composition pour la prévention ou le traitement d'une maladie du foie métabolique
EP3758716A4 (fr) Formulations pour le traitement du reflux acide comprenant de l'alginate de sodium
IL284988A (en) A pharmaceutical preparation containing mesitantan for the treatment of chronic thromboembolic pulmonary hypertension
EP3768274A4 (fr) Composition destinée à être utilisée dans le traitement d'états provoqués par une déficience en calcium
EP3522983A4 (fr) Compositions à base de cromolyne pour le traitement d'une fibrose pulmonaire
EP3827831A4 (fr) Composition pharmaceutique pour la prévention ou le traitement de la stéatohépatite non alcoolique
EP4181915A4 (fr) Compositions pour le traitement de l'obésité
EP3795170C0 (fr) Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne
EP4021480A4 (fr) Peptides pour le traitement de troubles rénaux
EP3858351A4 (fr) Composition pharmaceutique pour le traitement de la fibrose
EP4340881A4 (fr) Anticorps pour le traitement d'alpha-synucléinopathies
EP3979817A4 (fr) Composition pour l'inhibition de transporteur de prostaglandines et applications thérapeutiques associées